Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Diacomit Stiripentol Dravet Syndrome List with criteria/condition Complete
Dificid fidaxomicin Clostridium difficile infection N/A Withdrawn
Dificid Fidaxomicin Clostridium difficile infection Do not list at the submitted price Complete
Dojolvi triheptanoin Long-chain fatty acid oxidation disorders Reimburse with clinical criteria and/or conditions Complete
Doptelet avatrombopag Chronic immune thrombocytopenia (ITP) Do not reimburse Complete
Dovato dolutegravir / lamivudine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Duaklir Genuair Aclidinium bromide/formoterol fumarate dihydrate Chronic obstructive pulmonary disease List with clinical criteria and/or conditions Complete
Duobrii Halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Duodopa Levodopa / carbidopa Parkinson's disease Do not list Complete
Duodopa Levodopa / carbidopa (Drug Plan Submission) Parkinson's disease Reimburse with clinical criteria and/or conditions Complete